Engineering safer neuropsychiatric compounds

Safety
Achieved
Through
Engineering.

We design molecules and therapies to improve clinical efficacy while reducing physical and psychological risks

Our
Pipeline

Arcadia Medicine is advancing a pipeline of promising therapeutic candidates designed to address mental health disorders that were previously intractable or inadequately addressed with existing therapeutics.

Drug

In Development

Preclinical

Phase I/II

Phase III

AM-1002

PTSD
(Post-Traumatic Stress Disorder)

AM-1002 is a phenethylamine empathogen which has been optimized for use in drug-assisted psychotherapy for patients suffering from PTSD. AM-1002’s composition has been optimized to produce a shorter time course and safer non-neurotoxic drug profile, as compared to MDMA.

AM-1004

MDD
(Major Depressive Disorder)

AM-1004 is a combination (psychoactive-empathogen) product designed for the treatment of major depression. Its profile has been generated to produce fewer negative psychological and physical side effects compared to psilocybin therapy and to have a shorter time course.

AM-1006

SA
(Substance Abuse)

AM-1006 is an internasal low-dose psychoactive product which has been designed to produce a short acting effect for optimized use in a traditional hour-long therapeutic setting.  

Our
Pipeline

Arcadia Medicine is advancing a pipeline of promising therapeutic candidates designed to address mental health disorders that were previously intractable or inadequately addressed with existing therapeutics

PRECLINICAL

AM-1002

PTSD (Post-Traumatic Stress Disorder)

AM-1002’s composition has been optimized to produce a shorter time course and safer non-neurotoxic drug profile, as compared to MDMA.

IN DEVELOPMENT

AM-1004

MDD (Major Depressive Disorder)

AM-1004 is a combination (psychoactive-empathogen) product designed for the treatment of major depression. Its profile has been generated to produce fewer negative psychological and physical side effects compared to psilocybin therapy and to have a shorter time course.

IN DEVELOPMENT

AM-1006

SA (Substance Abuse)

AM-1006 is an internasal low-dose psychoactive product which has been designed to produce a short acting effect for optimized use in a traditional hour-long therapeutic setting.  

Discovery Platform

Predict

Arcadia’s computational generative model identifies psychoactive candidates of interest by identifying an optimal drug pharmacology and profile based on a large assortment of data and relevant safety parameters.

Select

Top candidates and combinations are identified and evaluated based on their pharmacology, pharmacokinetics, and half-life to ensure a safe and effective drug profile.

Learn

Our process continuously generates large datasets, which is used to continuously curate and improve the prediction process before and during the clinical evaluation process.

Team

Team

Chief Executive Officer and Founder

Nikita Obidin

Vice President of Regulatory Affairs

GARY RIORDAN

Chief of Staff

JACLYN CHAU

Head of Strategy and Operations

Serena Lim-strutt

Core CMC Partner

JOan connolly

Advisors

Scientific Advisor

Boris Heifets

Scientific Advisor

Graham Pechenik

Strategic advisor

Sarah Sclarsic

Strategic Advisor

JAMIE HEYWOOD

Strategic Advisor

QUINTIN FRERICHS

Contact Us

Name

ADDRESS

1160 Battery Street, Suite 100
San Francisco, CA, 94111

EMAIL